Diagnostics.sk

SDS according to directive EC 1907/2006 (REACH), EC 1272/2008 (CLP) Version: 1.0 Product code: 2008 1.12.2011 SAFETY DATA SHEET
1 – IDENTIFICATION OF SUBSTANCE / AGENT AND COMPANY / FIRM Identification of substance / agent: Diagnostic strip for proof of β-lactamase by chromogenic cephalosporin. Identification of company / firm: Organization: National toxicological information centre, Limbová 5, 833 05 Bratislava Product is not classified as dangerous according to directives of European Union. 3 – COMPOSITION / INFORMATION ON INGREDIENTS Product does not contain components classified as dangerous according to directives of European Union. As components of product are in solid form impregnated on filtration paper, product is not recognized as threat for health when instructions of leaflet are kept. _________________________________________________________________________________________________________________ For extinguishing use these sorts of fire extinguishers carbon dioxide, foam or dry chemical according to materials stored in Avoid contamination of system of surface or underground waters by water used for fire extinguishing. __________________________________________________________________________________________ Page 1 from 3
SDS according to directive EC 1907/2006 (REACH), EC 1272/2008 (CLP) Version: 1.0 Product code: 2008 1.12.2011 Liquidate used or unused product as dangerous waste. 8 – EXPOSURE CONTROLS / PERSONAL PROTECTION Product does not contain materials with exposure limits. Additional information in section 11 – Toxicological information Product is in form of plastic strip with fixed paper zone, impregnated by ingredients. There is no quantitative information about toxicity of product available. Product must be handled with caution usual for chemicals. Page 2 from 3
SDS according to directive EC 1907/2006 (REACH), EC 1272/2008 (CLP) Version: 1.0 Product code: 2008 1.12.2011 There is no reason to expect ecological problems, if product is handled and used with proper caution and attention. __________________________________________________________________________________________ Product disposal must be made according to official regulations. Packaging disposal must be made according to official regulations. Product is not classified as dangerous according to transport regulations. Take into consideration directive 94/33/ES about protection of young people at work. _________________________________________________________________________________________________________________ - __________________________________________________________________________________________ Information stated in this safety data sheet is based on current state of our knowledge. It characterises product with consideration on adequate safety measures. It does not represent warranty of material properties. Page 3 from 3

Source: http://www.diagnostics.sk/quality/preview-file/sds-2008-482.pdf

farmakonomuddannelsen.dk

Pharm World Sci (2006) 28:239–247DOI 10.1007/s11096-006-9023-9Drug-related problems in patients with angina pectoris, type 2diabetes and asthma – interviewing patients at homeLotte Stig Haugbølle Æ Ellen Westh SørensenReceived: 12 January 2006 / Accepted: 12 April 2006 / Published online: 26 October 2006Ó Springer Science+Business Media B.V. 2006‘‘Other problems’’ (such as limi

Fdl122002

Dec. 20, 2002 THE FOOD & DRUG LETTER Issue No. 666 Dec. 20, 2002 CLARITIN APPROVAL MARKS SIGNIFICANT SHIFT IN RX-TO-OTC SWITCHES The switch of Schering-Plough’s Claritin to over-the-counter (OTC) status set new precedents whoseimplications will reach far beyond drugstore shelves and affect the pharmaceutical industry for years. FDA’s Nov. 27 approval of OTC Claritin, the

Copyright ©2010-2018 Medical Science